Leiomyosarcoma — Trials

Leiomyosarcoma — Trials · CancerIndex

Clinical trials

Registered studies

135 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 38
Recruiting: 25
Ph III recruiting: 2
Growth YoY: —
Industry share: 16%
Top sponsor: National Cancer Institute (NCI)
Termination share: 40.4%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (23)

clinicaltrialsPublishedShowing 51–78 of 78 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT00025220	Thalidomide in Treating Patients With Recurrent or Persistent Cancer of the Uterus	completed	Phase 2	60	National Cancer Institute (NCI)NIH	1	Jul 23, 2019	clinicaltrials
NCT00378911	Sunitinib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus	completed	Phase 2	44	National Cancer Institute (NCI)NIH	1	Jul 23, 2019	clinicaltrials